FDA 483 OBSERVATION · #15 OF 1,923 MOST-CITED
Purchasing controls, Lack of or inadequate procedures
FDA cited this observation 933 times across 818 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
The firm lacked adequate procedures to ensure that purchased or otherwise received products and services conform to specified requirements — including evaluating and selecting suppliers on the basis of their ability to meet requirements.
Why FDA writes it — A device is only as controlled as its supply chain. Without purchasing controls, nonconforming components and unqualified contract services enter the product with no gate — so FDA treats supplier control as a front-line quality-system requirement.
- Evaluate and select suppliers, contractors, and consultants on their ability to meet specified requirements, including quality requirements, and document the basis.
- Define the type and extent of control you apply to each supplier proportionate to the product or service and its effect on finished-device quality.
- Establish and maintain quality requirements — and, where warranted, quality agreements — that suppliers must meet, and keep records of acceptable suppliers.
- Re-evaluate suppliers when performance or nonconformances indicate the control level should change.
- Suppliers approved once on price or availability and never re-evaluated against quality performance.
- No documented, risk-based control level — every supplier treated the same regardless of how critical their input is.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.4× the rate of the average FDA-cited firm (11.1% vs 7.8%), across 818 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Procedures to ensure that all purchased or otherwise received product and services conform to specified requirements have not been established.
Procedures to ensure that all purchased or otherwise received product and services conform to specified requirements have not been adequately established.
Procedures to ensure that all purchased or otherwise received product and services conform to specified requirements have not been adequately established.
Procedures to ensure that all purchased or otherwise received product and services conform to specified requirements have not been adequately established.
Procedures to ensure that all purchased or otherwise received product and services conform to specified requirements have not been adequately established.
Procedures to ensure that all purchased or otherwise received product and services conform to specified requirements have not been adequately established.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →